Randomized Phase II Trial Comparing Amrubicin With Topotecan in Patients With Previously Treated Small-Cell Lung Cancer: North Japan Lung Cancer Study Group Trial 0402
Akira Inoue(Tohoku University Hospital), Toshihiro Nukiwa(Tohoku University), Toumei Tsukamoto(Sendai Kousei Hospital), Shingo Takanashi(Sendai Kousei Hospital), Hiroshi Yokouchi(Fukushima Medical University), Fumihiro Hommura(Sendai Kousei Hospital), Yasuo Saijo(Niigata University), Shunichi Sugawara(Sendai Kousei Hospital), Toshiro Suzuki(Sendai Kousei Hospital), Hiroshi Watanabe(Sendai Kousei Hospital), Chieko Inoue(Sendai Kousei Hospital), Minoru Inage(Sendai Kousei Hospital), Kazunori Gomi(Tohoku University), Osamu Ishimoto(Sendai Kousei Hospital), Koichi Yamazaki(Hokkaido University Hospital), Makoto Maemondo(Miyagi Prefectural Hospital Organization)
Cited by 235
Related Papers
Gefitinib or Chemotherapy for Non–Small-Cell Lung Cancer with Mutated EGFR
|New England Journal of Medicine|2010|5.6k
Adjuvant atezolizumab after adjuvant chemotherapy in resected stage IB–IIIA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase 3 trial
|The Lancet|2021|1.5k
Nrf2 Redirects Glucose and Glutamine into Anabolic Pathways in Metabolic Reprogramming
|Cancer Cell|2012|1.4k
Double-blind, Placebo-controlled Trial of Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis
|American Journal of Respiratory and Critical Care Medicine|2005|953